Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RioDerm-003 by Rion for Radiodermatitis: Likelihood of Approval
RioDerm-003 is under clinical development by Rion and currently in Phase I for Radiodermatitis. According to GlobalData, Phase I drugs...